Sanofi-Aventis is set to sell $4 billion in Euro-denominated bonds, divided into two tranches of $2 billion each: one with four-year maturities and the other with seven-year maturities. So far this year, drugmakers have been successful with bond investors on both sides of the Atlantic, with Roche completing record issues in both U.S. and Euro markets. Report